A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas

A clinical review of treatment outcomes in glioblastoma multiforme—the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?

(2012) K Rock et al.   BRITISH JOURNAL OF RADIOLOGY

Individualized Targeted Therapy for Glioblastoma

(2012) Michael Weller et al.   CANCER JOURNAL

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

(2012) Tareq A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

Lapatinib for Advanced or Metastatic Breast Cancer

(2012) F. L. Opdam et al.   ONCOLOGIST

Genetic profile of astrocytic and oligodendroglial gliomas

(2011) Hiroko Ohgaki et al.   Brain Tumor Pathology

Bevacizumab in glioblastoma multiforme

(2011) Pol Specenier   Expert Review of Anticancer Therapy

Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas

(2011) Michael Weller et al.   GLIA

Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of ΔEGFR

(2011) Vaibhav Chumbalkar et al.   JOURNAL OF PROTEOME RESEARCH

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

(2011) D.-S. Kong et al.   NEURO-ONCOLOGY

Molecular targeting of glioblastoma: Drug discovery and therapies

(2011) Ren-Yuan Bai et al.   TRENDS IN MOLECULAR MEDICINE

Molecular diagnostics of gliomas: state of the art

(2010) Markus J. Riemenschneider et al.   ACTA NEUROPATHOLOGICA

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Automated Extraction of DNA and RNA from a Single Formalin-Fixed Paraffin-Embedded Tissue Section for Analysis of Both Single-Nucleotide Polymorphisms and mRNA Expression

(2010) G. Hennig et al.   CLINICAL CHEMISTRY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma

(2010) Florian Stockhammer et al.   JOURNAL OF NEURO-ONCOLOGY

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

(2009) Brian Thiessen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

EGF receptor inhibitors in the treatment of glioblastoma multiform: Old clinical allies and newly emerging therapeutic concepts

(2009) Macoura Gadji et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

The transcriptional network for mesenchymal transformation of brain tumours

(2009) Maria Stella Carro et al.   NATURE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats

(2008) L. Aubry et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

What is the relevance of determining EGFR-variant-III status in glioblastomas?

(2008) Antonio MP Omuro   Nature clinical practice. Oncology

Mechanisms of Disease: temozolomide and glioblastoma—look to the future

(2008) Maciej M Mrugala et al.   Nature clinical practice. Oncology